Following a recent peer-reviewed publication describing the use of C-Stem™ for massive stem cell expansion, Maxime Feyeux, PhD, co-founder and Chief Scientific Officer of TreeFrog Therapeutics, highlights how this platform can impact the manufacturing of stem-cell-derived therapies.
Transcript:
In this paper, we demonstrate that C-Stem™ is a good means to amplify massively pluripotent stem cells. The question is: can we bring something further to the field?
What we’ve demonstrated with that paper is that you can have a massive amplification of pluripotent stem cells with a very good quality of your cells. But is that the extent of what you can do with C-Stem™? and what C-Stem™ can bring to the field? That’s really not the way I see it. I think that you can see C-Stem™ as a platform, that can help you at each and every step of the development of your cell therapy product. It’s comparable to CRISPR: it’s something that helps you have a robust outcome, and being agile in your development. With C-Stem™ you can use the same exact platform – technological platform – to get massive amplification of your pluripotent stem cells – you make a master cell bank – you de-risk the genomic integrity of your cells, … Then you use the same platform to differentiate to get your specific cell type. You get the advantage of bioreactors. You can scale it up. You can control better the outcome of your cells. And then and you also have another part which is that when you want to integrate your cells in a given indication you want the functionality, you want the engraftment. And basically going for a microtissue approach gives you that extra boost as compared to single cells, which are going to be stressed upon engraftment and maybe not perform as well.